- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00685659
Effectiveness of Extended Treatments for Drug Dependence (ETDD)
Study Overview
Status
Conditions
Detailed Description
There is considerable evidence that treatment for drug use disorders can lead to substantial improvements in substance use and psychosocial problem severity. However, a significant percentage of patients relapse to problematic levels of substance use after primary treatment, and require additional treatment episodes. Patients are therefore frequently referred to continuing care programs to prevent relapse and decrease the probability of additional rehabilitation treatments. However, current models of continuing care may not be adequate for the long-term management of a chronic, relapsing disorder such as substance dependence. One possible approach for improving the management of drug dependence is adaptive treatment regimes, which combine low intensity monitoring and counseling when patients are doing well with stepped care protocols to increase the intensity of treatment when warranted by deteriorations in status and functioning. However, addiction management protocols may require incentives and other features to make long-term participation more appealing.
Cocaine dependent patients who have completed 2 weeks of intensive outpatient treatment (IOP) will be randomly assigned to one of the following interventions: (1) continued participation in IOP without additional intervention (TAU); (2) TAU plus an adaptive protocol that includes monitoring, feedback, and brief counseling via telephone on a tapered schedule out to 24 months, and more intensive face-to-face treatment when warranted (TMAC); or (3) TAU and the adaptive protocol, plus incentives for sustained participation (TMAC-Plus). Patients will be followed up at 3, 6, 9, 12, 18, and 24 months post intake into the study. Follow-up assessments will include measures of drug use, treatment process and potential mediating factors, psychosocial problem severity, utilization of health and social services, and costs.
The two adaptive extended interventions (TMAC and TMAC-Plus) are predicted to produce better drug use outcomes than TAU. TMAC-Plus is hypothesized to produce better retention and drug use outcomes than TMAC. Economic analyses will determine the cost-effectiveness and benefit-cost of TMAC and TMF-Plus relative to TAU, and to each other. Other analyses will test mediation hypotheses, examine potential moderator effects, and test the impact of disease management on HIV risk behaviors.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Presbyterian Hospital
-
Philadelphia, Pennsylvania, United States, 19123
- NorthEast Treatment Centers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- qualify for a DSM-IV lifetime diagnosis of cocaine dependence and cocaine use in 6 months prior to treatment;
- initial engagement in IOP, as indicated by attendance at 4 or more sessions in the first two weeks of treatment;
- 18 to 75 years of age;
- willingness to be randomized and participate in research.
- metropolitan area residents;
- able to provide the name, verified telephone number, and address of at least one contact who can provide locator information on the patient during follow-up.
Exclusion Criteria:
- current psychotic disorder or evidence of dementia severe enough to prevent participation in outpatient treatment;
- acute medical problem requiring immediate inpatient treatment;
- current participation in methadone or other forms of DA treatment, other than IOP
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: TAU only
Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
|
9 hours of group counseling per week for 2-3 months
|
Experimental: TMAC only
Adaptive telephone-based counseling
|
In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas.
Adaptive stepped care algorithm is included
|
Experimental: TMAC plus
Adaptive telephone-based counseling, plus incentives
|
In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas.
Adaptive stepped care algorithm and monetary incentives for participation are included
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abstinence
Time Frame: 3 month follow up
|
Abstinence as reported on Addiction Severity Index, Timeline Follow up, and as tested on the urine drug screen.
Measure was created as such: if on ASI the participant reported no use, and on the TLFB the participant reported no use, and on the urine drug screen there was no substances detected, then the participant is considered abstinent.
If there is use indicated on any one or all of those items (ASI, TLFB, UDS) then the participant is not abstinent.
|
3 month follow up
|
Abstinence
Time Frame: 6 month follow up
|
Abstinence as reported on Addiction Severity Index, Timeline Follow up, and as tested on the urine drug screen.
Measure was created as such: if on ASI the participant reported no use, and on the TLFB the participant reported no use, and on the urine drug screen there was no substances detected, then the participant is considered abstinent.
If there is use indicated on any one or all of those items (ASI, TLFB, UDS) then the participant is not abstinent.
|
6 month follow up
|
Abstinence
Time Frame: 9 month follow up
|
Abstinence as reported on Addiction Severity Index, Timeline Follow up, and as tested on the urine drug screen.
Measure was created as such: if on ASI the participant reported no use, and on the TLFB the participant reported no use, and on the urine drug screen there was no substances detected, then the participant is considered abstinent.
If there is use indicated on any one or all of those items (ASI, TLFB, UDS) then the participant is not abstinent.
|
9 month follow up
|
Abstinence
Time Frame: 12 month follow up
|
Abstinence as reported on Addiction Severity Index, Timeline Follow up, and as tested on the urine drug screen.
Measure was created as such: if on ASI the participant reported no use, and on the TLFB the participant reported no use, and on the urine drug screen there was no substances detected, then the participant is considered abstinent.
If there is use indicated on any one or all of those items (ASI, TLFB, UDS) then the participant is not abstinent.
|
12 month follow up
|
Abstinence
Time Frame: 18 month follow up
|
Abstinence as reported on Addiction Severity Index, Timeline Follow up, and as tested on the urine drug screen.
Measure was created as such: if on ASI the participant reported no use, and on the TLFB the participant reported no use, and on the urine drug screen there was no substances detected, then the participant is considered abstinent.
If there is use indicated on any one or all of those items (ASI, TLFB, UDS) then the participant is not abstinent.
|
18 month follow up
|
Abstinence
Time Frame: 24 month follow up
|
Abstinence as reported on Addiction Severity Index, Timeline Follow up, and as tested on the urine drug screen.
Measure was created as such: if on ASI the participant reported no use, and on the TLFB the participant reported no use, and on the urine drug screen there was no substances detected, then the participant is considered abstinent.
If there is use indicated on any one or all of those items (ASI, TLFB, UDS) then the participant is not abstinent.
|
24 month follow up
|
Cocaine Urine Toxicology
Time Frame: 3 month follow up
|
Positive cocaine test of urine
|
3 month follow up
|
Cocaine Urine Toxicology
Time Frame: 6 month follow up
|
Positive cocaine test of urine
|
6 month follow up
|
Cocaine Urine Toxicology
Time Frame: 9 month follow up
|
Positive cocaine test of urine
|
9 month follow up
|
Cocaine Urine Toxicology
Time Frame: 12 month follow up
|
Positive cocaine test of urine
|
12 month follow up
|
Cocaine Urine Toxicology
Time Frame: 18 month follow up
|
Positive cocaine test of urine
|
18 month follow up
|
Cocaine Urine Toxicology
Time Frame: 24 month follow up
|
Positive cocaine test of urine
|
24 month follow up
|
Comparison Across Groups in Societal Costs
Time Frame: 24 months
|
Total savings/spending calculated as the monetary value of days of illegal activity, days experiencing medical problems, days experiencing psychiatric problems, and days in jail captured with the ASI.
Presented in 2008 dollars.
|
24 months
|
Net Saving/Spending Comparisons Across Groups From Provider Perspective
Time Frame: 24 months
|
Savings minus intervention costs.
Presented in 2008 dollars.
|
24 months
|
Net Comparisons of Savings and Spendings Across Groups From Societal Perspective
Time Frame: 24 months
|
Savings minus intervention costs.
Presented in 2008 dollars.
|
24 months
|
Percent Days Cocaine Use
Time Frame: 3 months (approximately study days 1 - 90)
|
Percent of days during the follow up that there was any cocaine use
|
3 months (approximately study days 1 - 90)
|
Percent Days Cocaine Use
Time Frame: 6 months (approproximately study days 91 - 180)
|
Percent of days during the follow up that there was any cocaine use
|
6 months (approproximately study days 91 - 180)
|
Percent Days Cocaine Use
Time Frame: 9 months (approximately study days 181 - 270)
|
Percent of days during the follow up that there was any cocaine use
|
9 months (approximately study days 181 - 270)
|
Percent Days Cocaine Use
Time Frame: 12 months (approximately study days 271 - 365)
|
Percent of days during the follow up that there was any cocaine use
|
12 months (approximately study days 271 - 365)
|
Percent Days Cocaine Use
Time Frame: 18 months (approximately study days 366 - 546)
|
Percent of days during the follow up that there was any cocaine use
|
18 months (approximately study days 366 - 546)
|
Percent Days Cocaine Use
Time Frame: 24 months (approximately study days 547 - 730)
|
Percent of days during the follow up that there was any cocaine use
|
24 months (approximately study days 547 - 730)
|
Percent Days Abstinent
Time Frame: 3 months (approximately study days 1 - 90)
|
Percent of days during the follow up that participant was abstinent from Alcohol and Cocaine
|
3 months (approximately study days 1 - 90)
|
Percent Days Abstinent
Time Frame: 6 months (approximately study days 91 - 180)
|
Percent of days during the follow up that participant was abstinent from Alcohol and Cocaine
|
6 months (approximately study days 91 - 180)
|
Percent Days Abstinent
Time Frame: 9 months (approximately study days 181 - 270)
|
Percent of days during the follow up that participant was abstinent from Alcohol and Cocaine
|
9 months (approximately study days 181 - 270)
|
Percent Days Abstinent
Time Frame: 12 months (approximately study days 271 - 365)
|
Percent of days during the follow up that participant was abstinent from Alcohol and Cocaine
|
12 months (approximately study days 271 - 365)
|
Percent Days Abstinent
Time Frame: 18 months (approximately days 366 - 546)
|
Percent of days during the follow up that participant was abstinent from Alcohol and Cocaine
|
18 months (approximately days 366 - 546)
|
Percent Days Abstinent
Time Frame: 24 months (approximately study days 547 - 730)
|
Percent of days during the follow up that participant was abstinent from Alcohol and Cocaine
|
24 months (approximately study days 547 - 730)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participation in Protocol
Time Frame: 24 months
|
Percent available sessions completed
|
24 months
|
HIV Sex Risk Score
Time Frame: 12 months
|
Risk score from RAB: Risk Assessment Battery.
The RAB is a 41 - item self report developed to study the transmission of HIV.
The Risk Assessment Battery generates a drug-risk score and a sex-risk score.
For this study, the sex-risk score was used as the outcome measure of sexual behavior that is associated with HIV transmission.
The sex-risk score ranges from 0 to 18, with 0 denoting no sex-risk and 18 denoting highest sex-risk.
Previous research among drug using populations have found a sex-risk score mean of 6.2.
|
12 months
|
HIV Sex Risk Score
Time Frame: 24 months
|
Risk score from RAB: Risk Assessment Battery.
The RAB is a 41 - item self report developed to study the transmission of HIV.
The Risk Assessment Battery generates a drug-risk score and a sex-risk score.
For this study, the sex-risk score was used as the outcome measure of sexual behavior that is associated with HIV transmission.
The sex-risk score ranges from 0 to 18, with 0 denoting no sex-risk and 18 denoting highest sex-risk.
Previous research among drug using populations have found a sex-risk score mean of 6.2.
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James R McKay, Ph.D., University of Pennsylvania
Publications and helpful links
General Publications
- McKay JR, Van Horn DH, Lynch KG, Ivey M, Cary MS, Drapkin ML, Coviello DM, Plebani JG. An adaptive approach for identifying cocaine dependent patients who benefit from extended continuing care. J Consult Clin Psychol. 2013 Dec;81(6):1063-73. doi: 10.1037/a0034265. Epub 2013 Sep 16.
- McKay JR, Van Horn DH, Lynch KG, Ivey M, Cary MS, Drapkin M, Coviello D. Who benefits from extended continuing care for cocaine dependence? Addict Behav. 2014 Mar;39(3):660-8. doi: 10.1016/j.addbeh.2013.11.019. Epub 2013 Dec 1.
- McKay JR, Van Horn D, Rennert L, Drapkin M, Ivey M, Koppenhaver J. Factors in sustained recovery from cocaine dependence. J Subst Abuse Treat. 2013 Aug;45(2):163-72. doi: 10.1016/j.jsat.2013.02.007. Epub 2013 Apr 2.
- Van Horn DH, Drapkin M, Ivey M, Thomas T, Domis SW, Abdalla O, Herd D, McKay JR. Voucher incentives increase treatment participation in telephone-based continuing care for cocaine dependence. Drug Alcohol Depend. 2011 Apr 1;114(2-3):225-8. doi: 10.1016/j.drugalcdep.2010.09.007. Epub 2010 Nov 1.
- Wimberly AS, Ivey M, Rennert L, McKay JR. Effect of Continuing Care for Cocaine Dependence on HIV Sex-Risk Behaviors. AIDS Behav. 2017 Apr;21(4):1082-1090. doi: 10.1007/s10461-016-1434-6.
- McCollister K, Yang X, McKay JR. Cost-effectiveness analysis of a continuing care intervention for cocaine-dependent adults. Drug Alcohol Depend. 2016 Jan 1;158:38-44. doi: 10.1016/j.drugalcdep.2015.10.032. Epub 2015 Nov 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01DA020623 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine Dependence
-
W. Michael HootenNational Institute on Drug Abuse (NIDA)Recruiting
-
University of ArkansasNational Institute on Drug Abuse (NIDA); Baylor College of MedicineCompleted
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence | Cocaine Dependence | Methamphetamine DependenceUnited States
-
Tong LeeNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedCocaine Dependence | Methamphetamine DependenceUnited States
-
The University of Texas Health Science Center,...National Institute on Drug Abuse (NIDA)RecruitingAlcohol Dependence | Substance Abuse | Cocaine Dependence | Opiate Dependence | Cocaine AbuseUnited States
-
Johns Hopkins UniversityCompletedBehavior, Addictive | Heroin Dependence | Opioid Dependence | Cocaine Dependence | Cocaine AbuseUnited States
-
Wayne State UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Heroin Dependence | Cocaine Abuse or DependenceUnited States
-
University of PennsylvaniaCompletedCocaine DependenceUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use Disorder | Cocaine Use Disorder | Cocaine Dependence | Methamphetamine Dependence | Stimulant Use Disorder | Methamphetamine Abuse | Cocaine Abuse | Stimulant Abuse | Stimulant UseUnited States
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterVA Mental Illness Research, Education and Clinical CentersCompletedCannabis Dependence | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Dependence | Opiate DependenceUnited States
Clinical Trials on Intensive Outpatient Treatment
-
Dartmouth-Hitchcock Medical CenterNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompleted
-
Brown UniversityNational Institute of Mental Health (NIMH)Completed
-
University of Texas Southwestern Medical CenterCompletedSuicidal Ideation | Suicide, AttemptedUnited States
-
The University of Texas Health Science Center at...University of Pennsylvania; Brooke Army Medical Center; C.R.Darnall Army Medical... and other collaboratorsCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)CompletedDrug DependenceUnited States
-
National Development and Research Institutes, Inc.National Institute on Drug Abuse (NIDA)Completed
-
University of California, Los AngelesNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Matrix Institute...CompletedAlcohol Use Disorder | Social Anxiety DisorderUnited States
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Norwegian Foundation for Health and RehabilitationCompletedAnorexia Nervosa | Bulimia Nervosa | Eating Disorder | Personality DisorderNorway
-
University of WashingtonNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | SuicideUnited States
-
Hanoi Medical UniversityCompleted